Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  ALK-Abello A/S    ALK B   DK0060027142

ALK-ABELLO A/S (ALK B)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
12/11/2017 12/12/2017 12/13/2017 12/14/2017 12/15/2017 Date
744(c) 735(c) 726.5(c) 725(c) 728 Last
16 779 23 002 22 712 33 641 4 049 Volume
0.00% -1.21% -1.16% -0.21% +0.41% Change
More quotes
Financials ( DKK)
Sales 2017 2 937 M
EBIT 2017 67,8 M
Net income 2017 -0,33 M
Debt 2017 613 M
Yield 2017 0,67%
Sales 2018 2 948 M
EBIT 2018 -38,7 M
Net income 2018 -186 M
Debt 2018 1 201 M
Yield 2018 0,70%
P/E ratio 2017 5 059,32
P/E ratio 2018
EV / Sales2017 2,71x
EV / Sales2018 2,90x
Capitalization 7 343 M
More Financials
Company
ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies.It also manufactures tablet-based allergy vaccines for pollen, house dust mites, animals and insect stings.Its treatment comprises of allergy vaccines, emergency treatment and allergy... 
Sector
Pharmaceuticals
Calendar
02/06Earnings Release
More about the company
Surperformance© ratings of ALK-Abello A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on ALK-ABELLO A/S
12/07 ALK ABELLO A/S : Pricing and further details on the offering of new shares in al..
12/06 ALK ABELLO A/S : Abelló a/s to issue up to 92,076 aa shares and up to 920,760 b ..
12/04 ALK ABELLO A/S : Denmark's Alk Abello suspends dividend to support North America..
11/28 ALK ABELLO A/S : to launch updated corporate strategy on 4 December
11/07ALK-ABELLO A/S : quaterly earnings release
11/03 ALK ABELLO A/S : Release date of nine-month interim report (Q3) 2017 and audio c..
10/12 ALK ABELLO A/S : Notification of ownership in ALK
09/27 ALK ABELLO A/S : partner, Torii, gains approval for Japanese cedar SLIT-tablet i..
09/21 ALK ABELLO A/S : acts on French injunction by accelerating investments in its qu..
09/14 ALK ABELLO A/S : Successful Phase III trial for ALK's tree allergy SLIT-tablet
More news
Sector news : Pharmaceuticals - NEC
08:48aDJTEVA PHARMACEUTICAL INDUSTRIES : Generics Giant Cuts Staff by 25% -- WSJ
07:34aDJNOVARTIS : Oncology CEO Bruno Strigini to Retire
12:05a Wall Street falls as investors fret about tax bill passage
12/14 TSX in broad retreat led by Cenovus, other energy stocks
12/14 Perrigo lines up bid for Merck's consumer health unit - sources
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/05 Alk Abello AS (AKBLF) - Investor Presentation - Slideshow
11/30 Pricing set in France for ALK's dust-mite allergy pill Acarizax
11/13 Alk Abello AS ADR 2017 Q3 - Results - Earnings Call Slides
08/21 ALK accelerates commercial launch of dust mite tablet in North America to Q4;..
08/16 ALK-ABELLO AS B SHS 2017 Q2 - Results - Earnings Call Slides
Chart ALK-ABELLO A/S
Duration : Period :
ALK-Abello A/S Technical Analysis Chart | ALK B | DK0060027142 | 4-Traders
Technical analysis trends ALK-ABELLO A/S
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Average target price 897  DKK
Spread / Average Target 24%
EPS Revisions
Managers
NameTitle
Carsten Hellmann President & Chief Executive Officer
Steen Riisgaard Chairman
Flemming Pedersen Chief Financial Officer & Executive Vice President
Henrik Hugo Jacobi Executive Vice President-Research & Development
Anders Gersel Pedersen Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALK-ABELLO A/S-19.13%1 162
JOHNSON & JOHNSON21.53%383 877
NOVARTIS12.01%221 304
PFIZER10.04%218 400
ROCHE HOLDING LTD.3.40%210 833
MERCK AND COMPANY-6.96%155 214